Ignite Creation Date:
2024-05-06 @ 1:05 AM
Last Modification Date:
2024-10-26 @ 10:58 AM
Study NCT ID:
NCT01720264
Status:
COMPLETED
Last Update Posted:
2019-01-08
First Post:
2012-10-30
Brief Title:
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
Sponsor:
Sherif S Farag
Organization:
Indiana University
Study Overview
Official Title:
A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation recovery of blood counts after transplant
Detailed Description:
Umbilical cord blood UCB is more commonly used for transplantation in children but is being used in adults more often However because adults are larger than children the relatively smaller stem cell dose in UCB is major limitation for transplantation in adults and engraftment can be delayed This study is trying to find out if the drug sitagliptin can be used to increase and speed up engraftment in adults receiving UCB transplantation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1R01HL112669-01 | NIH | None | httpsreporternihgovquickSearch1R01HL112669-01 |